Camurus AB (Sweden) Today
| CAMX Stock | SEK 573.00 12.00 2.14% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Camurus AB is selling for under 573.00 as of the 25th of November 2024; that is 2.14 percent increase since the beginning of the trading day. The stock's last reported lowest price was 562.5. Camurus AB has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Camurus AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Camurus AB , a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company was founded in 1991 and is headquartered in Lund, Sweden. The company has 55.42 M outstanding shares. More on Camurus AB
Moving together with Camurus Stock
Moving against Camurus Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Camurus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Camurus AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Camurus AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Fredrik Tiberg |
| Business Concentration | Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
Camurus AB (CAMX) is traded on Stockholm Exchange in Sweden and employs 170 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 13.96 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Camurus AB's market, we take the total number of its shares issued and multiply it by Camurus AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Camurus AB operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 55.42 M outstanding shares.
Camurus AB has accumulated about 411.57 M in cash with (143.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.74.
Check Camurus AB Probability Of Bankruptcy
Ownership AllocationCamurus AB holds a total of 55.42 Million outstanding shares. Camurus AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Camurus Ownership Details
Camurus AB Risk Profiles
Although Camurus AB's alpha and beta are two of the key measurements used to evaluate Camurus AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.71 | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.72 | |||
| Risk Adjusted Performance | (0.07) |
Camurus Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Camurus AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Camurus AB Corporate Directors
| Mark Never | Independent Director | Profile | |
| PerAnders Abrahamsson | Independent Director | Profile | |
| Kerstin Strinnholm | Independent Director | Profile | |
| Behshad Sheldon | Independent Director | Profile |
Additional Tools for Camurus Stock Analysis
When running Camurus AB's price analysis, check to measure Camurus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Camurus AB is operating at the current time. Most of Camurus AB's value examination focuses on studying past and present price action to predict the probability of Camurus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Camurus AB's price. Additionally, you may evaluate how the addition of Camurus AB to your portfolios can decrease your overall portfolio volatility.